Mutagenesis Advance Access published online on December 8, 2006
Mutagenesis, doi:10.1093/mutage/gel063
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute of Cancer Research, Section of Molecular Carcinogenesis, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK
* To whom correspondence should be addressed. Speakers: Volker M.Arlt (Institute of Cancer Research, UK), Frederick A.Beland (National Center for Toxicological Research; USA), Karen Brown (University of Leicester, UK), Erwin Eder (University of Würzburg, Germany), Gerhard Eisenbrand (University of Kaiserslautern, Germany), Peter B.Farmer (Biocentre Leicester, UK), Panagiotis Georgiadis (National Hellenic Research Foundation, Greece), Hansruedi Glatt (German Institute of Human Nutrition, Germany), Roger W.Godschalk (University of Maastricht, The Netherlands), Arthur P.Grollman (State University of New York at Stony Brook, USA), Monica Hollstein (German Cancer Research Center, Germany), Werner Lutz (University of Würzburg, Germany), Matilde M.Marques (Technical University of Lisbon, Portugal), Lennart Möller (Karolinska Institute, Sweden), Christopher J.Michejda (National Cancer Institute Frederick, USA), Jagadeesan Nair (German Cancer Research Center, Germany), Marco Peluso (Tuscany Cancer Institute, Italy), Wolfgang Pfau (GAB-Consulting; Germany), David H.Phillips (Institute of Cancer Research, UK), Elmar Richter (University of Munich, Germany), Heinz H.Schmeiser (German Cancer Research Center, Germany), Oliver J.Schmitz (University of Wuppertal, Germany), Bernadette Schoket (National Institute of Environmental Health, Hungary), Dan Segerbäck (Karolinska Institute, Sweden), Albrecht Seidel (Biochemical Institute for Environmental Carcinogens, Germany), Marie Stiborova (Charles University Prague, Czech Republic), Jan Topinka (Institute of Experimental Medicine AS, Czech Republic). Of all the chemicals classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC), 90% exert their biological effects through binding of their metabolically activated intermediates to DNA forming covalent DNA adducts. As a consequence DNA adducts are generally considered to be causative and directly related to tumour formation. DNA adduct analyses reflect tissue-specific rates of adduct formation and removal, which depend on carcinogen uptake, metabolic activation, DNA repair, adduct instability and tissue turnover and are thus useful markers of carcinogen exposure. The measurement of carcinogen-DNA adduct levels is central to the understanding of chemical carcinogenesis both in animals and humans to determine molecular mechanisms and exposure. Sensitive methods for DNA adduct analysis used to date are based on 32P-postlabelling, immunoassay, mass spectrometry and laser-induced fluorescence. The aim of this workshop held over 2 days (29-30 September 2006) at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, was to discuss methodological improvements of DNA adduct detection with emphasis on the 32P-postlabelling procedure as well as new findings achieved by applying the methods to studies on understanding human cancer mechanisms and to elucidate the relationship between adduct formation and human cancer risk.
Received October 30, 2006
Revised October 31, 2006
Meeting Report
ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006
Volker M. Arlt 1 *, Eva Frei 2, and Heinz H. Schmeiser 2
2 German Cancer Research Center, Division of Molecular Toxicology, INF 280, 69120 Heidelberg, Germany
Volker M. Arlt, E-mail: volker.arlt{at}icr.ac.uk
![]()
Abstract
This workshop was dedicated to Prof. Manfred Wiessler, head of the Division of Molecular Toxicology at the German Cancer Research Center, Heidelberg, Germany, on the occasion of his 65th birthday.
![]()
CiteULike
Connotea
Del.icio.us What's this?